Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Flanders Website

Kathleen C. Flanders, Ph.D.

Selected Publications

1)  Latella G, Vetuschi A, Sferra R, Zanninelli G, D'Angelo A, Catitti V, Caprilli R, Flanders KC, Gaudio E.
Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis.
Eur. J. Clin. Invest. 39: 145-56, 2009.
[Journal]
2)  Latella G, Vetuschi A, Sferra R, Catitti V, D'Angelo A, Zanninelli G, Flanders KC, Gaudio E.
Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice.
Liver Int. 2009.
[Journal]
3)  Flanders KC, Wakefield LM.
Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression.
Journal of mammary gland biology and neoplasia. 14: 131-44, 2009.
[Journal]
4)  Flanders KC, Ho BM, Arany PR, Stuelten C, Mamura M, Paterniti MO, Sowers A, Mitchell JB, Roberts AB.
Absence of Smad3 induces neutrophil migration after cutaneous irradiation: possible contribution to subsequent radioprotection.
Am. J. Pathol. 173: 68-76, 2008.
[Journal]
5)  Saika S, Yamanaka O, Flanders KC, Okada Y, Miyamoto T, Sumioka T, Shirai K, Kitano A, Miyazaki K, Tanaka S, Ikeda K.
Epithelial-mesenchymal transition as a therapeutic target for prevention of ocular tissue fibrosis.
Endocrine, metabolic & immune disorders drug targets. 8: 69-76, 2008.
[Journal]
6)  Arany PR, Flanders KC, Degraff W, Cook J, Mitchell JB, Roberts AB.
Absence of Smad3 confers radioprotection through modulation of ERK-MAPK in primary dermal fibroblasts.
J Dermatol Sci. 2007.
[Journal]
7)  Saika S, Yamanaka O, Okada Y, Miyamoto T, Kitano A, Flanders KC, Ohnishi Y, Nakajima Y, Kao WW, Ikeda K.
Effect of overexpression of ppar{gamma} on the healing process of corneal alkali burn in mice.
Am. J. Physiol., Cell Physiol. 293: C75-86, 2007.
[Journal]
8)  Saika S, Yamanaka O, Nishikawa-Ishida I, Kitano A, Flanders KC, Okada Y, Ohnishi Y, Nakajima Y, Ikeda K.
Effect of Smad7 gene overexpression on transforming growth factor beta-induced retinal pigment fibrosis in a proliferative vitreoretinopathy mouse model.
Arch. Ophthalmol. 125: 647-54, 2007.
[Journal]
9)  Saika S, Shirai K, Yamanaka O, Miyazaki K, Okada Y, Kitano A, Flanders KC, Kon S, Uede T, Kao WW, Rittling SR, Denhardt DT, Ohnishi Y.
Loss of osteopontin perturbs the epithelial-mesenchymal transition in an injured mouse lens epithelium.
Lab. Invest. 87: 130-8, 2007.
[Journal]
10)  Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW.
Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.
Mol. Cancer Ther. 6: 154-62, 2007.
[Journal]
11)  Shirai K, Saika S, Tanaka T, Okada Y, Flanders KC, Ooshima A, Ohnishi Y.
A new model of anterior subcapsular cataract: involvement of TGFbeta/Smad signaling.
Mol. Vis. 12: 681-91, 2006.
[Journal]
12)  Saika S, Ikeda K, Yamanaka O, Flanders KC, Okada Y, Miyamoto T, Kitano A, Ooshima A, Nakajima Y, Ohnishi Y, Kao WW.
Loss of tumor necrosis factor alpha potentiates transforming growth factor beta-mediated pathogenic tissue response during wound healing.
Am. J. Pathol. 168: 1848-60, 2006.
[Journal]
13)  Arany PR, Flanders KC, Kobayashi T, Kuo CK, Stuelten C, Desai KV, Tuan R, Rennard SI, Roberts AB.
Smad3 deficiency alters key structural elements of the extracellular matrix and mechanotransduction of wound closure.
Proc. Natl. Acad. Sci. U.S.A. 103: 9250-5, 2006.
[Journal]
14)  Saika S, Ikeda K, Yamanaka O, Miyamoto T, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Nakajima Y, Kao WW, Flanders KC, Roberts AB.
Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali.
Am. J. Pathol. 166: 1405-18, 2005.
[Journal]
15)  Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, Flanders KC, Samuni AM, Felici A, Reiss M, Yarkoni S, Sowers A, Mitchell JB, Roberts AB, Russo A.
Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone.
J. Biol. Chem. 279: 15167-76, 2004.
[Journal]
16)  Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE, Byfield S, Felici A, Flanders KC, Walz TM, Roberts AB, Aplan PD, Balis FM, Letterio JJ.
Loss of Smad3 in acute T-cell lymphoblastic leukemia.
N. Engl. J. Med. 351: 552-9, 2004.
[Journal]
17)  Flanders KC.
Smad3 as a mediator of the fibrotic response.
International journal of experimental pathology. 85: 47-64, 2004.
[Journal]
18)  Saika S, Kono-Saika S, Tanaka T, Yamanaka O, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Yoo J, Flanders KC, Roberts AB.
Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice.
Lab. Invest. 84: 1245-58, 2004.
[Journal]
19)  Saika S, Kono-Saika S, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Flanders KC, Yoo J, Anzano M, Liu CY, Kao WW, Roberts AB.
Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury.
Am. J. Pathol. 164: 651-63, 2004.
[Journal]
20)  Saika S, Ikeda K, Yamanaka O, Sato M, Muragaki Y, Ohnishi Y, Ooshima A, Nakajima Y, Namikawa K, Kiyama H, Flanders KC, Roberts AB.
Transient adenoviral gene transfer of Smad7 prevents injury-induced epithelial-mesenchymal transition of lens epithelium in mice.
Lab. Invest. 84: 1259-70, 2004.
[Journal]
21)  Flanders KC, Major CD, Arabshahi A, Aburime EE, Okada MH, Fujii M, Blalock TD, Schultz GS, Sowers A, Anzano MA, Mitchell JB, Russo A, Roberts AB.
Interference with transforming growth factor-beta/ Smad3 signaling results in accelerated healing of wounds in previously irradiated skin.
Am. J. Pathol. 163: 2247-57, 2003.
[Journal]
22)  Cao Z, Flanders KC, Bertolette D, Lyakh LA, Wurthner JU, Parks WT, Letterio JJ, Ruscetti FW, Roberts AB.
Levels of phospho-Smad2/3 are sensors of the interplay between effects of TGF-beta and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells.
Blood. 101: 498-507, 2003.
[Journal]
23)  Flanders KC, Burmester JK.
Medical applications of transforming growth factor-beta.
Clinical medicine & research. 1: 13-20, 2003.
[Journal]
24)  Roberts AB, Russo A, Felici A, Flanders KC.
Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta.
Ann. N. Y. Acad. Sci. 995: 1-10, 2003.
[Journal]
25)  Longenecker G, Thyagarajan T, Nagineni CN, Flanders KC, Factor V, Miller G, Ward JM, Nalca A, Rangnekar VM, Thorgeirsson S, Kulkarni AB.
Endocrine expression of the active form of TGF-beta1 in the TGF-beta1 null mice fails to ameliorate lethal phenotype.
Cytokine. 18: 43-50, 2002.
[Journal]
26)  Flanders KC, Sullivan CD, Fujii M, Sowers A, Anzano MA, Arabshahi A, Major C, Deng C, Russo A, Mitchell JB, Roberts AB.
Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation.
Am. J. Pathol. 160: 1057-68, 2002.
[Journal]
27)  Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, Flanders KC.
Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis.
Cytokine Growth Factor Rev. 17: 19-27, 2005.
[Journal]
28)  Ashcroft GS, Mills SJ, Flanders KC, Lyakh LA, Anzano MA, Gilliver SC, Roberts AB.
Role of Smad3 in the hormonal modulation of in vivo wound healing responses.
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 11: 468-73, 2003.
[Journal]
29)  Flanders KC, Kim ES, Roberts AB.
Immunohistochemical expression of Smads 1-6 in the 15-day gestation mouse embryo: signaling by BMPs and TGF-betas.
Dev. Dyn. 220: 141-54, 2001.
[Journal]
30)  Roberts AB, Piek E, Böttinger EP, Ashcroft G, Mitchell JB, Flanders KC.
Is Smad3 a major player in signal transduction pathways leading to fibrogenesis?.
Chest. 120: 43S-47S, 2001.
[Journal]
31)  Kim RH, Flanders KC, Birkey Reffey S, Anderson LA, Duckett CS, Perkins ND, Roberts AB.
SNIP1 inhibits NF-kappa B signaling by competing for its binding to the C/H1 domain of CBP/p300 transcriptional co-activators.
J. Biol. Chem. 276: 46297-304, 2001.
[Journal]
32)  Zujewski J, Vaughn-Cooke A, Flanders KC, Eckhaus MA, Lubet RA, Wakefield LM.
Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system.
Breast Cancer Res. 3: 66-75, 2001.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 6/11/2009.